Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites.

NCT01852409 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT01852409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01852409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites.
Lead sponsor
Peking University
Phase
Phase 1
Overall status
Unknown status
Start date
May 31, 2013
Completion date
June 30, 2015
Enrollment
18 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

refractory malignant ascites